Literature DB >> 35246730

The unexpected impact of cabozantinib on red blood cells consumption in patients with transfusion-dependent thalassemia.

Silvia Costantini1, Antonella Meloni2, Anna Spasiano1, Patrizia Cinque1, Paolo Ricchi3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35246730     DOI： 10.1007/s00277-022-04810-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  2 in total

1.  Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.

Authors:  Ali T Taher; Zeynep Karakas; Elena Cassinerio; Noppadol Siritanaratkul; Antonis Kattamis; Aurelio Maggio; Stefano Rivella; Norbert Hollaender; Bruyère Mahuzier; Brian Gadbaw; Yesim Aydinok
Journal:  Blood       Date:  2017-11-02       Impact factor: 22.113

2.  Hedyotis diffusae Herba-Andrographis Herba inhibits the cellular proliferation of nasopharyngeal carcinoma and triggers DNA damage through activation of p53 and p21.

Authors:  Zhiqing Liu; Shan Mu; Sha Li; Jiao Liang; Yuanyuan Deng; Zuo Yang; Jiongke Li; Liu Cao; Qinwei Fu; Xiaodong Chen; Lingyan Ding; Rui Han; Qinxiu Zhang; Hui Xie
Journal:  Cancer Gene Ther       Date:  2021-11-09       Impact factor: 5.854
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.